Atlas Trials

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04696809 · COMPLETED

Trial details

NCT number
NCT04696809
Sponsor
Janssen Pharmaceutical K.K.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hematologic Malignancies
Start date
2021-02-22
Primary completion
2026-04-13
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.